The September DCI Seminar Series, to be held on Wednesday, September 22 via Zoom, will feature Luis Diaz, MD, head of the Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center.
The title of his talk is “Cancer Risk, Detection, and Interception.”
As a clinical scientist, Diaz has harnessed the power of cancer mutations as biomarkers in circulating tumor DNA and potent antigens and championed the use of checkpoint inhibitors in the treatment of patients with tumors with high mutational burden.
He and his team conceptualized and executed the landmark proof-of-concept study using PD-1 blockade in patients with MSI-H, which led to the historic first pan-tumor FDA approval for any solid tumors with this genetic lesion in May 2017.
In 2019, he was awarded the Waun Ki Hong Award for Outstanding Achievement in Cancer Research. He is also the leader of the Stand Up to Cancer (SU2C) Colon Cancer Dream Team, editor-in-chief of Cancer Discovery and is an elected member of the American Society of Clinical Investigation (ASCI).
Prior to his appointment in December 2016 as head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, Diaz was a faculty member and physician at the Johns Hopkins University School of Medicine, a member of the Ludwig Center for Cancer Genetics and Therapeutics, and director of the Swim Across America Laboratory.
Diaz's lecture begins at 8 a.m. and ends at 9 a.m. The September DCI Seminar Series is presented by the DCI Cancer Risk, Detection & Interception Research Program and is held in conjunction with Hematology Oncology Grand Rounds.